DOSE PLASMA HOMOVANILLIC ACID LEVELS CHANGE WHEN SCHIZOPHRENIC PATIENTS GET WORSE?

1992 ◽  
Vol 15 ◽  
pp. 259B
Author(s):  
E. Suzuki ◽  
S. Kanba ◽  
M. Nibuya ◽  
F. Shintani ◽  
N. Kinoshita ◽  
...  
1993 ◽  
Vol 11 (1) ◽  
pp. 33-40 ◽  
Author(s):  
Charles L. Whelton ◽  
Ram N. Gupta ◽  
John M. Cleghorn ◽  
Shannon R. Ballagh

1974 ◽  
Vol 35 (4) ◽  
pp. 287-294 ◽  
Author(s):  
Bengt Fyr� ◽  
Birgitta Wode-Helgodt ◽  
Stefan Borg ◽  
G�ran Sedvall

1983 ◽  
Vol 142 (3) ◽  
pp. 288-291 ◽  
Author(s):  
W. F. Gattaz ◽  
H. Cramer ◽  
H. Beckmann

SummaryIncreasing evidence suggests that the concentrations of cyclic guanosine 3′5′-monophosphate (cGMP) in the cerebrospinal fluid (CSF) may reflect central cholinergic activity. When the concentrations of this nucleotide in the CSF from 28 schizophrenic patients (13 without and 15 with neuroleptic treatment) and 16 psychiatrically healthy controls was determined the schizophrenics showed significantly lower CSF levels of cGMP as compared to controls.As dopamine and homovanillic acid concentrations were not altered in these CSF samples, this finding of reduced cGMP suggests a cholinergic-dopaminergic imbalance in schizophrenia, with a reduction of the former and consequently a relative dominance of the latter.


1992 ◽  
Vol 15 ◽  
pp. 521A-522A ◽  
Author(s):  
M. DAVIDSON ◽  
R. S. KAHN ◽  
R. G. STERN ◽  
P. D. HARVEY ◽  
R. KEEFE ◽  
...  

2003 ◽  
Vol 60 (1) ◽  
pp. 98
Author(s):  
M. Bernardo ◽  
I. Baeza ◽  
R. Deulofeu ◽  
J. Goti ◽  
M.T. Plana

1997 ◽  
Vol 42 (1) ◽  
pp. 184S
Author(s):  
N. Aymard ◽  
I. Stein ◽  
A. Galinowski ◽  
A. Viala ◽  
F. Caroli ◽  
...  

Author(s):  
Mercedes Zumárraga ◽  
Ricardo Dávila ◽  
Miguel Angel González-Torres ◽  
Juan B. Anguiano ◽  
María José Zabalo ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document